Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
contact us
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Have a Project in Mind? Say Hi!
+1 800 123 456 789
+1 800 123 654 987
Mon - Sun: 10am - 10pm
27 Division St, New York,
NY 10002, USA
grido@mail.com
Newsroom
Press Releases
April 10, 2025
PR Neweswire
Qnovia, Inc. Announces Leadership Transition and Strategic Appointments to Support UK Commercialization Strategy
January 7, 2025
PR Neweswire
Qnovia, Inc. Announces First Patient Dosed in U.S. in Phase 1 study for RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
December 10, 2024
PR Neweswire
Qnovia, Inc. Raises $16 Million in Series B Financing to Advance Lead Asset RespiRx™ Nicotine Inhaler as a Prescription Smoking Cessation Therapy
October 21, 2024
PR Neweswire
Qnovia, Inc. CEO Speaks at FDA and NIH Public Meeting to Encourage Innovation of Smoking Cessation Treatment Options
October 1, 2024
PR Neweswire
Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
April 9, 2024
Business Wire
Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board
1
2
Media
October 25, 2024
Forbes
This Startup Has A New Way To Quit Smoking. Will this be the one that works?
October 2, 2024
Drug Delivery Business
Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy
December 4, 2023
Medical Device Network
Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study
April 4, 2023
Politico
Former FDA tobacco head: Smokers need a new tool to quit
March 31, 2023
Bloomberg
Ex-FDA Tobacco Head Advising Company on Smoker Cessation
February 24, 2023
Tobacco Reporter
Qnovia Raises $17 million for Nebulizer
January 8, 2023
Barron's
It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.
December 27, 2022
PharmaShots
Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding
December 19, 2022
Fierce Pharma
2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding
1
2
3
4
April 10, 2025
Qnovia, Inc. Announces Leadership Transition and Strategic Appointments to Support UK Commercialization Strategy
January 7, 2025
Qnovia, Inc. Announces First Patient Dosed in U.S. in Phase 1 study for RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
December 10, 2024
Qnovia, Inc. Raises $16 Million in Series B Financing to Advance Lead Asset RespiRx™ Nicotine Inhaler as a Prescription Smoking Cessation Therapy
October 25, 2024
This Startup Has A New Way To Quit Smoking. Will this be the one that works?
October 21, 2024
Qnovia, Inc. CEO Speaks at FDA and NIH Public Meeting to Encourage Innovation of Smoking Cessation Treatment Options
October 2, 2024
Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy
October 1, 2024
Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
April 9, 2024
Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board
December 4, 2023
Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study
1
2
3
…
5
#side-panel.side-panel {width: 500px;}#side-panel.side-panel .side-panel_sidebar {padding: 70px 0px 50px 60px;background-color: #FFFFFF;}
Qnovia
